Under AAAResearchReports.com Microscope: Pfizer Inc., Merck & Co. Inc., AbbVie
Inc., and Zogenix Inc.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, October 4, 2013
LONDON, October 4, 2013 /PRNewswire/ --
The U.S. equity market ended the day lower on Thursday, October 3, 2013. The
Dow Jones Industrial Average closed at 14,996.48, down 0.90%; the S&P 500
closed at 1,678.66, down 0.90%; and the NASDAQ Composite finished at 3,774.34,
down 1.07%. Shares in the drug manufacturing industry ended on a mixed note,
even as the broader market posted losses. The major movers in the industry
included Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie
Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). AAAResearchReports.com has
released full comprehensive research on PFE, MRK, ABBV, and ZGNX. These free
technical analyses can be downloaded by signing up at:
Pfizer Inc.'s shares fell by 0.83% on Thursday, tracking losses in the broader
market. The company's shares oscillated between$28.69 and $29.02before
ending the day at$28.77. A total of 22.69 million shares were traded, which
is below the daily average volume of 27.15 million. Despite Thursday's
decline, the company's shares have gained 4.05% in the previous three months
and 2.71% in the last one month, compared to a gain of 3.92% and 2.37% in the
S&P 500 during the respective periods. Moreover, Pfizer Inc.'s stock is
currently trading above its 50-day moving average of $28.53. A free technical
analysis on PFE available by signing up at:
Shares in Merck and Co. Inc. fluctuated between gains and losses before
finishing the day nearly flat on Thursday. The company's shares ended the day
at$48.36, down 0.02%, after fluctuating between$48.00 and$48.75 during the
trading session. A total of 17.90 million shares were traded, which is above
the daily average volume of 12.16 million. The company's shares have advanced
1.58% in the last three trading sessions and 2.44% in the previous one month,
compared to a loss of 0.17% and a gain of 2.37% in the S&P 500 during the
respective periods. Further, Merck and Co. Inc.'s stock is trading above its
50-day and 200-day moving averages of $47.77 and $47.13, respectively.
Register today and access free research on MRK at:
On Thursday, AbbVie Inc.'s stock advanced to close at $46.01, up 0.13% from
the previous day's closing price of $45.95. The company's shares oscillated
between $45.10 and $46.34 during the trading session. A total of 7.02 million
shares were traded, which is above the daily average volume of 4.04 million.
The company's shares are up 8.03% in the previous one month and 8.95% in the
last three months, compared to a gain of 2.37% and 3.92% in the S&P 500 during
the respective periods. Additionally, AbbVie Inc.'s stock is trading above its
50-day and 200-day moving averages of $44.50 and $43.75, respectively. The
free report on ABBV can be downloaded by signing up now at:
On Thursday, shares in Zogenix Inc. rallied 11.61%, extending the gains from
the previous trading session. The company's shares ended the day at $2.50
after vacillating between$2.25 and $2.65 during the trading session. A total
of 3.78 million shares were traded, which is above the daily average volume of
0.54 million. The company's stock has surged 63.40% in the previous three
months and 39.66% in the last one month, outperforming the S&P 500 which has
advanced 3.92% and 2.37% during the respective periods. Furthermore, Zogenix
Inc.'s stock is trading above its 50-day and 200-day moving averages of $1.79
and $1.66, respectively.
A free report on ZGNX can be accessed by registering at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: +1(646)396-9126, Peter F. Jones, email@example.com
Press spacebar to pause and continue. Press esc to stop.